CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens were evaluated before and during an anti-HCV regimen (interferon-a2a and ribavirin) in 36 patients coinfected with HCV and human immunodeficiency virus (HIV), to determine whether immune responses against HCV antigens are present in such patients, whether these responses are modified by anti-HCV treatment, and whether they are correlated with treatment efficacy. The CD4 responses against HCV antigens (primarily core antigens) detected at study entry in one-half of the patients did not correlate with anti-HCV treatment efficacy. Of 36 patients, 8 had patterns of persistent immune response to infection by genotypes 3 or 4 that were significantly correlated with sustained virologic response. Persistent immunologic reactivity and sustained virologic response coexisted only in patients infected with genotype 3. These findings suggest that HCV genotype may influence specific immune response, which, in turn, is implicated in virologic control.
users [3] . Improved survival of HIV-infected persons who are receiving highly active antiretroviral therapy (HAART) requires that chronic hepatitis C be effectively treated in patients who are coinfected [3] .
HIV infection modifies the natural history of chronic hepatitis C [4] . In HIV-infected patients, HCV-related liver disease is more severe, develops faster, and leads to cirrhosis more frequently [5] . HCV plasma loads are higher in coinfected patients [6, 7] , which suggests that viral replication is enhanced. Host factors, including the impact of HIV infection on the immune system, may contribute to this adverse course. On the other hand, chronic hepatitis C does not appear to alter the natural history of HIV infection [8] , although a few reports suggest that it does [9] . Data in the literature suggest that HCV infection is partially controlled by neutralizing antibodies [10] and CD8 cytotoxic T lymphocyte (CTL) responses [11] . The presence of strong CD4 and CTL functions is associated with resolution of acute hepatitis [12] [13] [14] [15] . CTL are thought to eliminate the infected hepatocytes, and CD4 T cells secrete cytokines essential for CTL and humoral responses. The ability of CD4 T lymphocytes to recognize HCV antigens can be assessed by their in vitro proliferative responses to these antigens.
The CD4 T cell response has been evaluated in immunocompetent patients. A strong response to structural and regulatory viral proteins has been reported in persons with acute hepatitis C who clear the virus [12] [13] [14] [15] . The immune systems of patients who develop chronic hepatitis C either do not mount an HCV-specific CD4 response or fail to sustain an initial strong response [12] . The percentage of chronic hepatitis patients who exhibit CD4 responses varies by report. These responses are directed either against structural and nonstructural (NS) proteins [16] [17] [18] [19] [20] or, according to recent reports, primarily against the structural core protein [14, 21, 22] . The intensity of the responses observed in patients with chronic hepatitis is lower than that in patients with acute hepatitis [12, 14] . The few longitudinal studies that have focused on HCV-infected patients indicate that treatment with interferon (IFN)-a enhances the frequency and the magnitude of specific responses to HCV antigens [20, 21] . In patients treated with IFN, reactivity to core protein is associated with viral clearance and favorable outcome [21] , whereas induction of responses to NS3 is observed regardless of the treatment result [23] . In HCV-HIV-coinfected patients, CD4 response against HCV antigens is expected to be impaired, but this has only been evaluated in a single report [24] .
In the present study, we evaluated the CD4 cell function in IFN-and ribavirin-treated patients coinfected with HCV and HIV who had CD4 cell counts of у cells/L. We sought 6 250 ϫ 10 to determine whether in vitro CD4 response to HCV antigens persists in immunodeficient patients, and, if so, whether the level of response at study entry would be predictive of the efficacy of anti-HCV treatment, of whether treatment could induce or amplify in vitro proliferative responses, and whether anti-HCV treatment efficacy is associated with improved immune reactivity.
Patients, Materials, and Methods
Patients. The 36 patients in the present study were enrolled in clinical trial ROCO, which was being conducted to evaluate the efficacy of 2 anti-HCV treatment regimens in patients coinfected with HCV and HIV. This was an open-labeled, randomized trial. Patients 18-65 years old who had chronic hepatitis C and HIV infection were eligible for the study.
The criteria for chronic HCV infection were positive results of testing (using Ortho HCV 3.0 ELISA Monolisa Anti-HCV, a thirdgeneration test; Sanofi Diagnostics Pasteur) of serum for anti-HCV antibodies, positive results of polymerase chain reaction assay for HCV RNA, a finding of elevated serum alanine aminotransferase levels at least twice during the year before study entry, and histologic confirmation of chronic hepatitis (with or without cirrhosis) by liver biopsy, according to METAVIR score [25] . Patients who had received anti-HCV medication in the past were excluded from the study.
HIV infection was confirmed by positive results of ELISA and Western blot assays. In all patients, CD4 T lymphocyte counts were /L and plasma HIV RNA levels were !10,000 6 1 250 cells ϫ 10 copies/mL (tested using bDNA Quantiplex HIV 3.0; Bayer Diagnostic) at least twice within the year before study entry. No inclusion or exclusion criteria existed for antiretroviral therapy; all antiretroviral treatments were allowed.
Patients were given IFN-a2a (Roféron; Produits Roche) for 48 weeks; patients in group A received 6 megaunits (MU) 3 times a week for 24 weeks and 3 MU 3 times a week for 24 weeks, and patients in group B received 9 MU daily for 2 weeks, 3 MU daily for 22 weeks, and 3 MU 3 times a week for 24 weeks. A qualitative technique was used to screen patients for serum HCV RNA at weeks 12, 48, and 72 (Cobas Amplicor HCV 2.0; Roche Molecular Diagnostics; threshold of detection, 100 copies/mL). Ribavirin (Produits Roche) was given in combination with IFN from week 16 through the end of treatment (week 48) to patients who did not have virologic responses at week 12.
For each patient, HCV was genotyped before treatment (InnoLIPA, HCV II; Innogenetics). At the same time, plasma HCV load was evaluated (Cobas Amplicor HCV Monitor 2.0 quantitative assay; Roche Molecular Diagnostics; threshold of detection, 1000 copies/mL). The control group included 8 healthy subjects who showed no evidence of having been exposed to HCV and HIV and who had negative results of testing with the reference ELISAs for anti-HCV and anti-HIV antibodies.
Proliferation assays. Antigen-specific proliferation assays were done at weeks 0, 2, 4, 8, 12, 24, 36, 48, 60, and 72. All tests were performed on Ficoll-Paque peripheral blood mononuclear cells (PBMC) from fresh blood samples harvested on glass beads (Amersham Pharmacia Biotech). PBMC (10 5 cells/well) were suspended in 200 mL of RPMI 1640 medium (Gibco Life Technologies) supplemented with 10% pooled heat-inactivated human AB serum, 2 mM L-glutamine (Gibco), 1 mM sodium pyruvate (Gibco), MEM nonessential amino acids (Gibco), penicillin (100 U/mL), and streptomycin (100 mg/mL) and incubated at 37ЊC with 5% CO 2 in 96-well U-bottom plates (Falcon; Subra) for 6 days. Each antigen or recombinant protein was tested in triplicate. The proliferative responses were evaluated by [ 3 H]thymidine uptake (1 mCi/well; Amersham Pharmacia Biotech) over the course of 18 h. Incorporated HCV recombinant proteins. The following segments of HCV proteins were obtained from Chiron: core (c22-3), aa 2-120; core, NS3, and NS4 (c25), aa 2-120 and 1192-1935; NS3 (c33c), aa 1192-1457; NS4 (c100-3), aa 1569-1931; NS3 and NS4 (c200), aa 1192-1931; NS4 (5-1-1), aa 1694-1735; and NS5 (NS5), aa 2024-2995. These proteins are expressed as C-terminal fusions with human superoxide dismutase (SOD) in yeast, Saccharomyces cerevisiae (c22-3, c200, c100-3, and NS5), or Escherichia coli (c-33 and 5-1-1). All antigens were 190% pure. Another set of recombinant HCV proteins expressed in E. coli was purchased from Mikrogen (core, aa 1-115; NS3, aa 1007-1534; and NS4, aa 1616-1862) and used to verify reactivity obtained with the Chiron proteins. Proteins from Mikrogen were 190% pure. They were synthesized using cDNA obtained from a cloned strain of genotype 1b. The Chiron proteins were obtained from the 1a prototypic sequence [26] . Proliferation assays were performed with Chiron and Mikrogen proteins at final concentrations of 5 and 2 mg/mL, respectively. A response was considered to be positive when reactivity was observed with proteins of both types.
HCV protein controls. Proliferation assays included yeast and E. coli controls. Their presence as contaminants in the proteins was considered negligible, because the patients who displayed signifi-cant positive reactions against E. coli and yeast had concomitant negative responses against the HCV antigens produced by yeast and E. coli systems. PBMC were also cultured in the presence of SOD, as a negative control. Proliferative responses for assays with SOD and without antigen were always identical. Contamination by endotoxin was evaluated by Limulus assay (Sigma Aldrich). Bacterial or fungal lipopolysaccharide content in HCV proteins at the concentration used in the tests was !30 or 30-50 pg/mL.
Synthetic peptides. Given that a positive reaction to core proteins has been reported in several healthy subjects [27] and that the recombinant proteins do not span the entire core region, all patients were tested using 20-or 24-mer peptides, corresponding to the core protein of the HCV 1a genotype (Chiron Mimotopes). These peptides are described as immunodominant T helper epitopes or immunogenic regions highly conserved among genotypes [17, 19, 20] . Peptides 1-4 lie within the region spanned by the core proteins. Peptides 5-7 are outside this region. Peptide 1 corresponded to aa 20-44; 2, to aa 55-74; 3, to aa 65-85; 4, to aa 79-103; 5, to aa 118-142; 6, to aa 129-152; and 7, to aa 148-172. We used these peptides at concentrations of 2.5-20 mg/mL.
HIV p24 and tuberculin. The HIV-1 p24 recombinant protein (Protein Science) derived from the HIV-1 gag gene (NY-5 strain) expressed in a baculovirus system was used at a final concentration of 0.5 mg/mL. Its purity was 190%. Baculovirus proteins were used as a control at 0.015 mg/mL (equal to the baculovirus protein concentration in the p24 recombinant protein). Purified protein derivative of tuberculin (Serum Statens Institute) was used at a final concentration of 1 mg/mL. Positive proliferation control was done using phytohemagglutinin (PHA; Murex Diagnostic) at 2 mg/ mL, supplemented with interleukin-2 at 20 IU/mL (R&D Systems Europe).
CD4 and CD8 cell depletion. Identification of the proliferating lymphocyte subsets was done by depleting PBMC of either the CD4 or CD8 populations by using immunomagnetic beads (Dynabeads; Dynal) coated with anti-CD4 and anti-CD8 antibodies. Proliferation assays were performed with the CD4-or CD8-depleted cell suspensions with the addition of gamma-irradiated (40 Gy) autologous PBMC ( cells/well) as providers of antigen-pre- 5 2 ϫ 10 senting cells (APCs).
Classification of patients by proliferative response to HCV antigens and HIV p24. We classified the patients by their immune proliferative response. Patients who had a positive proliferation assay positive against у1 specific HCV antigen before initiation of therapy were "initial immunologic responders." Initial immunologic responders who had positive results of у4 tests during followup, including 1 test after the end of treatment at weeks 60 or 72, were "persistent immunologic responders." The same criteria were used to classify patient responses to HIV-1 p24.
Statistical analysis. We analyzed results by Fisher's exact test, the Mann-Whitney nonparametric 2-tailed test, the x 2 test, and Pearson correlation coefficients, using GraphPad Prism 2.0 and Statistix software.
was considered to be statistically significant. For P р .05 the proliferation assays, the intensity of the response represented by the median SI and the interquartile range were calculated by taking into account all SI values. SI values below the cutoff value (р3) were included in the calculations as SI values of 1. Table 1 lists the characteristics of the 36 patients (26 men and 10 women) included in our study and the genotypes of HCV with which they were infected. According to the 1993 Centers for Disease Control and Prevention classification [28] , 23 of the 36 patients had stage A HIV infection, 8 had stage B infection, and 5 had stage C infection. Plasma HIV RNA levels were undetectable in 22 patients (61%). At study entry (week 0), the median CD4 lymphocyte count was
Results

Patients
The median of the 6 6 300 ϫ 10 1644 ϫ 10 lowest CD4 cell counts for individual patients (which usually occurred before any antiretroviral treatment had been administered) was cells/L (range, - 6 6 6 255 ϫ 10 7 ϫ 10 857 ϫ 10 cells/L). Thirty-three patients had received antiretroviral treatment for у6 months before study entry. For 14 of these patients, the antiretroviral therapy included 1 or 2 protease inhibitors (PIs). Three patients had not yet undergone treatment for HCV infection.
Fifteen patients were infected with HCV genotype 1; 1, with genotype 2; 13, with genotype 3; and 7, with genotype 4. For 27 patients, acquisition of HCV had occurred through intravenous drug use, and for 6, through transfusion of blood products. The route of acquisition could not be determined for 3 patients. The median estimated duration of HCV infection was 13.5 years (range, 5-15 years). Eight patients had severe fibrosis or cirrhosis (stage F3 or F4, according to the METAVIR score). The median HCV RNA plasma load at study entry was copies/mL (range, -copies/mL). 6 6 6 10.3 ϫ 10 0.25 ϫ 10 38.2 ϫ 10 Eighteen patients were included in treatment group A, and 13 were included in treatment group B.
Virologic Response to Anti-HCV Treatment
Among the 36 patients enrolled in the study, (patients 19 and 23) , the magnitude of responses increased during follow-up, whereas the level of response remained constant for the other 5 patients.
Ten patients (patients 4, 6-8, 11, 15, 20, 21, 34, and 36) had a response that began during the treatment and persisted for у3 tests. In 5 of these 10 patients, the response persisted after discontinuation of the treatment (patients 4, 7, 8, 11, and 20) . Only 1 patient (patient 16) did not have a response to core proteins at any point during follow-up. The median SI for the proliferative responses of the patients with persistent virologic responses did not differ at any stage of the follow-up period from that for patients who did not show virologic responses. The median SI value for all patients was 1 (range, 1-7) at study entry and did not vary significantly during the study.
Core peptides. Because the proliferation assay against purified peptides was introduced during the course of the study, some patients could not be tested at week 0. All 36 patients were tested 2-7 times between weeks 8 and 72. The results given -20  3  ---5  ---6  17  9  21   a   3  -ND  ND  -4  12  6  ---2 2  3  8  --3  ----8  1 7  24  3  --------13  8  26  3  7  -ND  ---15  ND  ND  ND  2 7  3  3  --------8  28  3  5  5  -11 
Phenotypes of proliferative T cell populations.
To identify the T cell population proliferating in response to HCV antigens, tests were performed after depletion of either CD4 or CD8 populations. In a representative experiment (figure 2), PBMC obtained from patient 23 were tested in the presence of core protein and peptide 7. CD8 depletion resulted in proliferation similar to that obtained with the whole population. In contrast, proliferation was abrogated by CD4 cell depletion, indicating that CD4 lymphocytes were the T cell subset predominantly involved in this proliferation. The addition of irradiated cells to act as APCs to replace the endogenous APCs, which were expected to be lost in the assay conditions, did not change the magnitude of response to core proteins but strongly enhanced the response to the peptide.
Correlation between proliferative responses and clinical, biological, and virologic parameters. At study entry, 19 patients were considered to be initial immunologic responders; among them, 5 patients had responses to core proteins only, 5 patients to core proteins and NS3, 5 patients to core proteins and NS4, 3 patients to NS3 only, and 1 patient to NS4 only. No significant difference was observed between initial immunologic responders and patients who had responses at other study points with regard to age, sex, lowest CD4 cell count, CD4 cell count at study entry, HCV RNA plasma load, HCV genotype (1-4 vs. 2 and 3), severity of hepatic lesions (METAVIR scores A1 and A2 vs. A3, and F1 and F2 vs. F3 and F4), or treatment with a PI at study entry. Patients infected with genotypes 1 and 4 were pooled, because both groups responded poorly to anti-HCV treatment [29, 30] .
Reactivity at study entry was not predictive of treatment outcome. Indeed, the proportion of initial immunologic responders to any HCV protein among patients who had a sustained virologic response and those who did not have a virologic response did not differ significantly ( ; Fisher's exact P p 1.0 test). In contrast, persistent immunologic responders were more likely to have a sustained virologic response. Reactivity to HIV p24 was serially evaluated during followup. Results are reported in figure 3 . At study entry, a positive response was observed in 15 patients (42%). The response frequency decreased until week 8, returned to baseline value at week 12, and then remained stable through week 72 but was lower than the initial value. These 15 patients (patients 2, 3, 6, 11, 12, 14, 17-19, 23-26, 28, and 32) were considered to be initial immunologic responders to p24. Ten of the 15 were persistent immunologic responders. The number of patients who had an initial response to p24 was significantly higher among initial immunologic responders to HCV (11 of 19 patients) than among patients who did not respond (4 of 17 patients) (P p ; Fisher's exact test). .048
The median SI value was 1 (range, 1-7) at study entry and did not significantly vary during the study. Patients who had an initial response to p24 and patients who did not respond were compared in terms of the following parameters: age, sex, lowest CD4 cell count, CD4 cell count at study entry, and treatment with a PI at study entry. We found no significant differences between the 2 groups. As was observed for HCV antigens, the number of positive tests was higher among patients with a sustained virologic response than among those with no virologic response (32 , by the x 2 test). P p .0002
Proliferative Responses to Tuberculin
The results of the proliferative tests against tuberculin are reported in figure 3 . A wide range of positive responses was observed, and positive responses were observed in most patients (97%) at study entry, with a median SI of 15 (range, 9-35.5). The magnitude of the response did not change significantly during follow-up. The lower the CD4 cell count before study entry, the less intense the response against tuberculin at study (5) 7 (39) 3 (17) 13 (72) 10 (55) 15 (83) NOTE. Data are for patients for whom у1 response to a given peptide was positive. For each patient, the results of 1 or 2 tests are reported. For each test, the reported stimulation index for protein and peptides corresponds to the same time point. When a single test is reported, core proteins and all peptides were tested in the same assay. When 2 tests are reported, peptides that could not be tested in a single assay were tested in a second assay; in such cases, the time point at which each assay was performed was precise. Nonsignificant stimulation indices (!3) are shown as dashes (-). NA, not applicable; NT, not tested. entry. A direct significant correlation was observed between the intensity of the tuberculin response and the lowest CD4 cell counts (Pearson correlation, ; ). The frer p 0.34 P p .005 quency of the responses decreased at weeks 2 and 4, returned to baseline values through week 48, and decreased again after treatment was completed. The proliferative responses of all patients to PHA did not differ from the responses of control subjects at study entry and decreased slightly during follow-up.
Proliferative Responses of Control Subjects
Proliferation tests were performed with PBMC obtained from 8 healthy control subjects who had negative results of testing for HIV and HCV. Proliferative responses against HCV recombinant proteins, HIV p24, and tuberculin were evaluated. One of the 8 control subjects displayed a weak response against core protein (SI, 4) and no responses to core peptides, and another control subject exhibited a weak response against NS3 (SI, 5) . No control subjects had responses to p24, and all responded to tuberculin.
Discussion
In patients solely infected with HCV who have chronic hepatitis C, the frequency of CD4 T cell responses and the antigens to which patients respond are variable [14] [15] [16] [17] [18] [19] [20] . Because of the impact of HIV on the immune system, one would expect the CD4 cell response to be altered in patients who are coinfected with HCV and HIV. In the present study, patients coinfected with HIV and HCV frequently displayed CD4 cell responses in the absence of anti-HCV treatment. This result may be related either to preservation of immune function in some patients or to restoration of immune function during HAART, for patients whose CD4 cell counts had been deeply reduced. Indeed, one-half of the patients included in the present study displayed HIV p24 reactivity, which is considered to be predictive of a favorable clinical course in HIV-infected long-term asymptomatic patients and to provide evidence of the ability of the immune system to respond to antigenic stimulation [31] . However, the absence of proliferative response to p24 does not necessarily correlate with immunodeficiency; the absence of such responses has been described in patients who experienced sustained suppression of virus load after initiation of HAART [32] . Although a wide range of response intensity was observed in the present study, the persistent reactivity to tuberculin, conceivably in the in vivo absence of the antigen, indicated that the immunologic memory was maintained in our patients and/ or possibly restored during effective anti-HIV therapy [33] .
The core protein was the most immunogenic at study entry and during follow-up; NS3 and NS4 were less frequently rec- ognized, and NS5 was never recognized. This could not be ascribed to the genotype 1 origin of the proteins we used, because our patients responded regardless of virus genotype. The frequency with which responses to core protein were seen may result from a higher level of conservation of the recognized epitopes than is the case for NS3, NS4, and especially NS5 proteins [34, 35] and/or from the presence of a wide range of T cell receptors capable of recognizing the epitopes. Because positive reactions against recombinant proteins have been detected in healthy persons who are not infected with HCV, the specificity of these proteins may appear to be questionable [27] . Consequently, reactivity to core protein was investigated using peptides in addition to recombinant proteins. Consistent results were obtained with these 2 antigenic materials, dismissing doubts as to their specificity. Such double-positive results were not observed in control subjects. Control subjects had responses only to core protein and did not respond to any peptide, which suggests that the response to core protein was nonspecific.
In our study, we looked for immunologic parameters predictive of the efficacy of treatment with IFN and ribavirin. At baseline, the existence of specific responses was not predictive of sustained virologic response. Furthermore, we did not find any relationship between proliferative response against HCV and different clinical and biological parameters. Unexpectedly, the lowest CD4 cell count and the CD4 cell count at study entry did not differ significantly between initial immunologic responders and patients who did not respond to treatment.
In the present study, responses to core protein dropped in frequency and amplitude early after initiation of the treatment and returned to values slightly higher than baseline. Few patients had responses to NS3 and NS4, and the magnitude of the responses was low. The number of patients who responded to p24 and tuberculin also decreased slightly soon after the initiation of treatment and did not return to baseline values after treatment completion. At present, we have no explanation for this early decrease in reactivity. That the treatment regimen and, notably, the high induction doses of IFN influenced reactivity is unlikely, because the transient lack of reactivity was independent of treatment group. We cannot exclude the possibility that HIV infection had a detrimental effect on CD4 immune responsiveness. In patients who were infected only with HCV, a relationship between treatment efficacy and an increase in the frequency and magnitude of CD4 proliferative responses against core protein has been reported [20, 21] . In our patients, the decreased ability of the treatment to improve reactivity to HCV may have contributed to its poor virologic efficacy.
In the present study, longitudinal follow-up revealed a pattern of sustained immune reactivity against HCV antigens in certain patients, of whom 2 had amplified responses to core protein. This pattern of persistent immune response was significantly associated with sustained virologic response to treatment. Moreover, a higher frequency of positive immune responses against HCV antigens and HIV p24 was observed among patients who had a sustained virologic response than among patients who did not respond to anti-HCV treatment, which emphasizes the association between efficient immune function and a virologic response to treatment. These data highlight the role of the anti-HCV CD4 response in viral clearance. However, 3 persistent immunologic responders did not clear the virus. Conversely, 3 patients who achieved viral clearance did not demonstrate sustained, if any, immune response. This confirms that virologic response is dependent on multiple host and viral factors [36] [37] [38] [39] .
Finally, all persistent immunologic responders were infected with HCV genotypes 3 or 4. Moreover, an association between persistent immune response and sustained virologic response was only observed in patients infected with a genotype 3 HCV.
None of the patients infected with genotype 1 were persistent immunologic responders, and only 1 had a sustained virologic response. Missale et al. [20] reported that CD4 response was dependent on genotype in patients infected with HCV alone. CD4 response was more frequent and was higher in magnitude for patients infected with genotype 2 than for those infected with genotype 1 [20] . Our results are in agreement with these data and suggest that the magnitude of the specific CD4 response could depend on HCV genotype. Diverse and well-documented viral mechanisms are involved in the resistance of genotype 1 to IFN [36, 37] .
In conclusion, CD4 response against HCV exists in patients coinfected with HCV and HIV. Notably, few CD4 responses were maintained or amplified during treatment in our study. Persistent immune response was significantly associated with a sustained virologic response. The few patients who displayed concomitant sustained virologic and immune responses were all infected with genotype 3 virus. This suggests that HCV genotype may influence the specific immune response, which in turn is implicated in viral control. Alternatively, genotype 3 may be more sensitive to effects of IFN, and suppression of viral replication may enhance immune responses, as has been reported for hepatitis B virus infection [40] .
